Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin plus Chloroquine for Uncomplicated P. falciparum Malaria
NCT00074841Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of azithromycin in Plasmodium falciparum malaria (2 arms), sponsored by Pfizer. Primary endpoint: Parasitological Clearance Rate at 28 days. Started Sep 2003; status: completed.
02
Drugs
azithromycin
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT00074841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074841.